vyn201
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 4, 2024 (NCT06493578)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Bromodomain-containing protein 3INHIBITOR
BRD3 inhibitor
- Bromodomain-containing protein 2INHIBITOR
BRD2 inhibitor
- Bromodomain-containing protein 1INHIBITOR
BRD1 inhibitor
- Bromodomain-containing protein 4INHIBITOR
BRD4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06493578 | Phase 2 | Jun 4, 2024 | Vyne Therapeutics Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vyne Therapeutics Inc. | For profit | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1